OncLive TV

Reva K. Basho, MD, discusses the integration of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Chad V. Pecot, MD, discusses the growth of actionable targets in lung cancer.

David Sallman, MD, discusses the efficacy of pevonedistat plus azacitidine in higher-risk myelodysplastic syndrome.

Daniel Pollyea, MD, MS, discusses emerging therapies in higher-risk myelodysplastic syndrome.

Catriona Jamieson, MD, PhD, discusses symptom management in patients with myelofibrosis.

Jean-Jacques Kiladjian, MD, PhD, discusses the potential utility of momelotinib in improving transfusion-independence rates in myelofibrosis.

Alan P. Venook, MD, discusses the unmet need addressed by the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Marin F. Xavier, MD, discusses recent updates in diffuse large B-cell lymphoma based on data from the 2021 ASCO Annual Meeting.

Jeremy C. Jones, MD, discusses targeting HER2 alterations in colorectal cancer.

Ricardo Costa, MD, MSc, discusses ongoing research efforts in triple-negative breast cancer.

Robert J. Motzer, MD, discusses the importance of assessing health-related quality of life in renal cell carcinoma.

Sairah Ahmed, MD, discusses optimizing treatment with axicabtagene ciloleucel in large B-cell lymphoma.

Paolo Ghia, MD, PhD, discusses key findings from the phase 2 CAPTIVATE trial in chronic lymphocytic leukemia.

Srdan Verstovsek, MD, PhD, discusses the efficacy of the combination of pelabresib plus ruxolitinib in the treatment of patients with myelofibrosis.

Christopher Flowers, MD, discusses the long-term efficacy with tafasitamab-cxix in combination with lenalidomide in diffuse large B-cell lymphoma.

Wen Wee Ma, MBBS, discusses first-line treatment considerations in metastatic pancreatic cancer.

Yung Lyou, MD, PhD, discusses emerging biomarkers in prostate cancer.

Betsy O'Donnell, MD, discusses the promise of novel targets in multiple myeloma.

Sajeve Samuel Thomas, MD, discusses the safety profile of lifileucel plus pembrolizumab in advanced melanoma.

Sara M. Tolaney, MD, MPH, discusses tailoring HER2-directed therapies in the treatment of patients with breast cancer. 

Dana Chase, MD, FACOG, discusses the importance of utilizing genetic testing to guide treatment decisions for patients with ovarian cancer.

Hiromichi Shirasu, MD, discusses the design of the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer.

Daniel Pollyea, MD, MS, discusses indications for anti-CD33 therapy in the treatment of patients with acute myeloid leukemia.

Ehab L. Atallah, MD, discusses the clinical implications of the phase 3 QUAZAR AML-001 trial in acute myeloid leukemia.

Mitchell R. Smith, MD, PhD, discusses the rationale for the phase 2 ECOG-ACRIN E1411 trial in mantle cell lymphoma.

Yung Lyou, MD, PhD, discusses optimal sequencing with apalutamide in prostate cancer.

Paul M. Barr, MD, discusses the clinical implications of the long-term results of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Peter Martin, MD, discusses the role of maintenance therapy with rituximab in mantle cell lymphoma.

Omar Nadeem, MD, discusses the uptake of novel therapies in heavily pretreated multiple myeloma.

Adam Sperling, MD, PhD, discusses future research with CAR T-cell therapy in multiple myeloma.